|
1.
|
|
10 p, 666.8 KB |
Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain
/
Arriola, Edurne (Hospital del Mar (Barcelona, Catalunya)) ;
García Gómez, Ramón (Hospital General Universitario Gregorio Marañón) ;
Diz Taín, Pilar (Hospital Universitario de León) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Martínez Aguillo, Maite (Complejo Hospitalario de Navarra) ;
Valdivia, Javier (Hospital Universitario Virgen de las Nieves (Granada)) ;
Paredes, Alfredo (Hospital de Donostia (Sant Sebastià, País Basc)) ;
Sánchez-Torres, José Miguel (Hospital Universitario de la Princesa (Madrid)) ;
Peralta Muñoz, Sergio (Hospital Universitari Sant Joan de Reus (Tarragona)) ;
Barneto Aranda, Isidoro (Hospital Universitario Reina Sofía (Córdoba, Espanya)) ;
Gutierrez, Vanesa (Hospital Regional Universitario Carlos Haya (Málaga)) ;
Andrade Santiago, Jesús Manuel (Hospital Virgen de la Salud (Toledo)) ;
Aparisi, Francisco (Hospital Virgen de los Lirios) ;
Isla, Dolores (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
Ponce, Santiago (Hospital 12 de Octubre (Madrid)) ;
Vicente Baz, David (Hospital Universitario Virgen Macarena (Sevilla, Andalusia)) ;
Artal, Ángel (Hospital Universitario Miguel Servet (Saragossa)) ;
Amador, Mariluz (AstraZeneca) ;
Provencio, Mariano (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Universitat Autònoma de Barcelona
Although the benefit of first-line epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKIs) over chemotherapy has been demonstrated in several clinical trials, data from clinical practice is lacking and the optimal EGFR TKI to be used remains unclear. [...]
2018 -  10.1186/s12885-018-4004-7
BMC Cancer, Vol. 18 Núm. 1 (30 2018) , p. 106
|
|
|
2.
|
|
12 p, 1.3 MB |
Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors
/
Serrano, Cesar (Vall d'Hebron Institut d'Oncologia) ;
Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
Matito, Judit (Vall d'Hebron Institut d'Oncologia) ;
Mancuso, Francesco M. (Vall d'Hebron Institut d'Oncologia) ;
Valverde, Claudia (Hospital Universitari Vall d'Hebron) ;
Quiroga, Sergi (Hospital Universitari Vall d'Hebron) ;
Landolfi, Stefania (Hospital Universitari Vall d'Hebron) ;
Castro, Sandra (Hospital Universitari Vall d'Hebron) ;
Dopazo, Cristina (Hospital Universitari Vall d'Hebron) ;
Sebio, Ana (Institut d'Investigació Biomèdica Sant Pau) ;
Virgili Manrique, Anna Cristina (Institut d'Investigació Biomèdica Sant Pau) ;
Menso, Maria M. (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Martín-Broto, J. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Sansó, Miriam (Vall d'Hebron Institut d'Oncologia) ;
García-Valverde, Alfonso (Vall d'Hebron Institut d'Oncologia) ;
Rosell Aluja, Jordi 1955- (Vall d'Hebron Institut d'Oncologia) ;
Fletcher, J.A. (Harvard Medical School) ;
George, S. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Carles, Joan (Hospital Universitari Vall d'Hebron) ;
Arribas, Joaquín V (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
Gastrointestinal stromal tumor (GIST) initiation and evolution is commonly framed by KIT/PDGFRA oncogenic activation, and in later stages by the polyclonal expansion of resistant subpopulations harboring KIT secondary mutations after the onset of imatinib resistance. [...]
2020 - 10.1186/s12885-020-6597-x
BMC Cancer, Vol. 20 Núm. 1 (may 2020) , p. 99
|
|
|
3.
|
|
10 p, 1.1 MB |
Monitoring and evaluation of breast cancer screening programmes : Selecting candidate performance indicators
/
Muratov, Sergei (McMaster University (Canadà)) ;
Canelo Aybar, Carlos Gilberto (Institut d'Investigació Biomèdica Sant Pau) ;
Tarride, Jean-Eric (McMaster University (Canadà)) ;
Alonso-Coello, Pablo (Institut d'Investigació Biomèdica Sant Pau) ;
Dimitrova, Nadya (Joint Research Centre) ;
Borisch, Bettina (University of Geneva) ;
Castells, Xavier (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Duffy, Stephen W. (Queen Mary University of London) ;
Fitzpatrick, Patricia (UCD School of Public Health) ;
Follmann, Markus (German Cancer Society) ;
Giordano, Livia (CPO-Piedmont - AOU Città della Salute e della Scienza) ;
Hofvind, Solveig (Cancer Registry of Norway) ;
Lebeau, Annette (University Medical Center Hamburg-Eppendorf) ;
Quinn, Cecily (Ordensklinikum Linz Elisabethinen) ;
Torresin, Alberto (ASST Grande Ospedale Metropolitano) ;
Vialli, Claudia (Joint Research Centre) ;
Siesling, Sabine (University of Twente) ;
Ponti, Antonio (CPO-Piedmont - AOU Città della Salute e della Scienza) ;
Giorgi Rossi, Paolo (AUSL Reggio Emilia. IRCCS) ;
Schünemann, Holger (McMaster University (Canadà)) ;
Nyström, Lennarth (Umeå University) ;
Broeders, Mireille (Radboud University Medical Center) ;
Autelitano, Mariangela ;
Colzani, Edoardo ;
Daneš, Jan ;
Gräwingholt, Axel ;
Ioannidou-Mouzaka, Lydia ;
Knox, Susan ;
Langendam, Miranda ;
McGarrigle, Helen ;
Pérez Gómez, Elsa ;
Van Engen, Ruben ;
Warman, Sue ;
Young, Kenneth ;
Van Landsveld-Verhoeven, Cary ;
Lerda, Donata ;
Saz-Parkinson, Zuleika ;
Parmelli, Elena ;
Janusch-Roi, Annett ;
Universitat Autònoma de Barcelona
In the scope of the European Commission Initiative on Breast Cancer (ECIBC) the Monitoring and Evaluation (M&E) subgroup was tasked to identify breast cancer screening programme (BCSP) performance indicators, including their acceptable and desirable levels, which are associated with breast cancer (BC) mortality. [...]
2020 - 10.1186/s12885-020-07289-z
BMC Cancer, Vol. 20 Núm. 1 (24 2020) , p. 795
|
|
|
4.
|
|
15 p, 1.6 MB |
The ABNL-MARRO 001 study : a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes
/
Moyo, Tamara K. (Vanderbilt University School of Medicine) ;
Mendler, Jason H (University of Rochester Medical Center) ;
Itzykson, Raphael (Paris Diderot University) ;
Kishtagari, Ashwin (Vanderbilt University School of Medicine) ;
Solary, Eric (Institut Gustave Roussy. Université Paris-Saclay) ;
Seegmiller, Adam C. (Vanderbilt University School of Medicine) ;
Gerds, Aaron T. (Cleveland Clinic) ;
Ayers, Gregory D. (Vanderbilt University School of Medicine) ;
Dezern, Amy E. (Johns Hopkins University) ;
Nazha, Aziz (Cleveland Clinic) ;
Valent, Peter (Ludwig Boltzmann Institute for Hematology and Oncology. Medical University of Vienna) ;
Onida, Francesco (University of Milan) ;
Van Azizan de Loosdrecht, Arjan A. (Amsterdam UMC. University Medical Center) ;
Pleyer, Lisa (Salzburg Cancer Research Institute Center for Clinical Cancer and Immunology Trials) ;
Xicoy Cirici, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Tibes, Raoul (Mayo Clinic) ;
Geissler, Klaus (Sigmund Freud University) ;
Komrokji, Rami S. (H. Lee Moffitt Cancer Center) ;
Zhang, Jing (University of Wisconsin-Madison) ;
Germing, Ulrich (Department of Hematology. Oncology. and Clinical Immunology. University of Duesseldorf) ;
Steensma, David P. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Wiseman, Daniel H. (University of Manchester) ;
Pfeilstöecker, Michael (Hanusch Hospital and Ludwig Boltzmann Institute for Hematology and Oncology) ;
Elena, Chiara (University of Pavia) ;
Cross, Nicholas C P (University of Southampton) ;
Luebbert, Michael (University of Freiburg) ;
Mesa, Ruben A. (Mays Cancer Center at UT Health San Antonio MD Anderson) ;
Montalban-Bravo, Guillermo (MD Anderson Cancer Center) ;
Sanz, G.F. (Hospital Universitari i Politècnic La Fe (València)) ;
Platzbecker, Uwe (University Hospital Leipzig) ;
Patnaik, Mrinal M. (Mayo Clinic) ;
Padron, Eric (H. Lee Moffitt Cancer Center) ;
Santini, Valeria (University of Florence) ;
Fenaux, Pierre (Paris Diderot University) ;
Savona, Michael R. (Vanderbilt University School of Medicine) ;
Universitat Autònoma de Barcelona
Background: Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) comprise several rare hematologic malignancies with shared concomitant dysplastic and proliferative clinicopathologic features of bone marrow failure and propensity of acute leukemic transformation, and have significant impact on patient quality of life. [...]
2022 - 10.1186/s12885-022-10073-w
BMC Cancer, Vol. 22 Núm. 1 (december 2022) , p. 1013
|
|
|
5.
|
|
10 p, 1.3 MB |
Application of One-Step Nucleic Acid Amplification (OSNA) in different cancer entities and usefulness in prostate cancer : a systematic review
/
Cuadras, Mercè (Hospital Universitari Vall d'Hebron) ;
Planas, Jacques (Hospital Universitari Vall d'Hebron) ;
Celma, Ana (Hospital Universitari Vall d'Hebron) ;
Regis, Lucas (Hospital Universitari Vall d'Hebron) ;
de Torres, Inés (Hospital Universitari Vall d'Hebron) ;
Semidey, M. Eugenia (Hospital Universitari Vall d'Hebron) ;
Trilla, Enrique (Hospital Universitari Vall d'Hebron) ;
Morote Robles, Juan (Universitat Autònoma de Barcelona. Departament de Cirurgia) ;
Universitat Autònoma de Barcelona
Lymph node (LN) status is a key prognostic factor in the decision-making process of different cancer entities, including prostate cancer (PCa). Sectioning and haematoxylin and eosin (H&E) staining technique remain the gold standard for the evaluation of LN metastases despite some limitations, especially low sensitivity in detecting an accurate tumour burden within the LN, as well as a subjective and time-consuming result. [...]
2022 - 10.1186/s12885-022-09355-0
BMC Cancer, Vol. 22 (april 2022)
|
|
|
6.
|
|
18 p, 2.6 MB |
Efficacy of systemic oncological treatments in patients with advanced esophageal or gastric cancers at high risk of dying in the middle and short term : an overview of systematic reviews
/
Santero, Marilina (Institut d'Investigació Biomèdica Sant Pau) ;
Bracchiglione, Javier (Universidad de Valparaíso) ;
Acosta-Dighero, Roberto (Universidad San Sebastian) ;
Meade, Adriana-Gabriela (Institut d'Investigació Biomèdica Sant Pau) ;
Antequera, Alba (Institut d'Investigació Biomèdica Sant Pau) ;
Auladell-Rispau, Ariadna (Institut d'Investigació Biomèdica Sant Pau) ;
Quintana Ruiz, Maria Jesús (Universitat Autònoma de Barcelona. Facultat de Medicina) ;
Requeijo, Carolina (Institut d'Investigació Biomèdica Sant Pau) ;
Rodríguez-Grijalva, G. (Institut d'Investigació Biomèdica Sant Pau) ;
Salas-Gama, Karla (Institut d'Investigació Biomèdica Sant Pau) ;
Dorantes-Romandia, R. (Institut d'Investigació Biomèdica Sant Pau) ;
Salazar, Josefina (Institut d'Investigació Biomèdica Sant Pau) ;
Solà, Ivan (Institut d'Investigació Biomèdica Sant Pau) ;
Urrútia, Gerard (Institut d'Investigació Biomèdica Sant Pau) ;
Bonfill, X. (Xavier) (Institut d'Investigació Biomèdica Sant Pau)
Esophageal and gastric cancers are a significant public health problem worldwide, with most patients presenting with advanced-stage disease and, consequently, poor prognosis. Systemic oncological treatments (SOT) have been widely used over more conservative approaches, such as supportive care. [...]
2021 - 10.1186/s12885-021-08330-5
BMC Cancer, Vol. 21 (june 2021)
|
|
|
7.
|
|
12 p, 1.2 MB |
Colorectal cancer health services research study protocol : the CCR-CARESS observational prospective cohort project
/
Quintana López, José María (Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC)) ;
Gonzalez, Nerea (Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC)) ;
Anton-Ladislao, Ane (Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC)) ;
Redondo, Maximino (Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC)) ;
Baré i Mañas, Marisa (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Fernandez de Larrea, Nerea (Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC)) ;
Briones, Eduardo (Salud Publica (Sevilla)) ;
Escobar, Antonio (Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC)) ;
Sarasqueta, Cristina (Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC)) ;
Garcia-Gutierrez, Susana (Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC)) ;
Aguirre, Urko (Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC)) ;
Universitat Autònoma de Barcelona
Colorectal cancers are one of the most common forms of malignancy worldwide. But two significant areas of research less studied deserve attention: health services use and development of patient stratification risk tools for these patients. [...]
2016 - 10.1186/s12885-016-2475-y
BMC Cancer, Vol. 16 (july 2016)
|
|
|
8.
|
|
12 p, 700.5 KB |
Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain : OSIREX-Spanish Lung Cancer Group
/
Provencio, Mariano (Universidad Autónoma de Madrid) ;
Terrasa, Josefa (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Garrido, Pilar (Instituto Ramón y Cajal de Investigación Sanitaria (Madrid)) ;
Campelo, Rosario García (Instituto de Investigación Biomédica de A Coruña) ;
Aparisi, Francisco (Hospital General Universitario de Valencia) ;
Diz Taín, Pilar (Complejo Asistencial Universitario de León) ;
Aguiar, David (Hospital Universitario de Gran Canaria Dr. Negrín) ;
García-Giron, Carlos (Hospital Universitario de Burgos) ;
Hidalgo, Julia (Hospital Lluís Alcanyis. Medical Oncology Department) ;
Aguado, Carlos (Hospital Clínico San Carlos (Madrid)) ;
González, Jorge García (Hospital Clínico Universitario (Santiago de Compostela, Galícia)) ;
Esteban, Emilio (Hospital Universitario Central de Asturias) ;
Gómez-Aldavarí, Lorenzo (Complejo Hospitalario Universitario de Albacete) ;
Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Juan, Óscar (Hospital Universitari i Politècnic La Fe (València)) ;
Chara, Luís Enrique (Hospital Universitario de Guadalajara) ;
Marti, Juan L. (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Castro, Rafael López (Hospital Clínico Universitario de Valladolid) ;
Ortega Granados, Ana Laura (Complejo Hospitalario de Jaén) ;
Moreno, Elia Martínez (Hospital Virgen de la Salud (Toledo)) ;
Coves, Juan (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
Sánchez Peña, Ana M. (Hospital Universitario de Getafe (Madrid)) ;
Bosch-Barrera, J (Hospital Universitari de Girona Doctor Josep Trueta) ;
Gastaldo, Amparo Sánchez (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Núñez, Natalia Fernández (Hospital Universitario Lucus Augusti (Lugo)) ;
Del Barco Morillo, Edel (Hospital Universitario de Salamanca) ;
Cobo, Manuel (Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Unidad de Gestión Clínica Intercentros de Oncología Médica) ;
Isla, Dolores (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Navarro, Fátima (Hospital Universitario Príncipe de Asturias (Alcalá de Henares, Madrid)) ;
Calvo, Virginia (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Universitat Autònoma de Barcelona
AURA study reported 61% objective response rate and progression-free survival of 9. 6 months with osimertinib in patients with EGFR/T790M+ non-small cell lung cancer. Due to lack of real-world data, we proposed this study to describe the experience with osimertinib in Spain. [...]
2021 - 10.1186/s12885-021-07922-5
BMC Cancer, Vol. 21 (march 2021)
|
|
|
9.
|
|
12 p, 1.2 MB |
Three-year outcome after transanal versus laparoscopic total mesorectal excision in locally advanced rectal cancer : a multicenter comparative analysis
/
De Lacy, F.B (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Roodbeen, S. X. (Cancer Center Amsterdam. Department of Surgery, Amsterdam University Medical Centers, University of Amsterdam) ;
Ríos, J. (Universitat Autònoma de Barcelona. Departament de Pediatria, Obstetrícia i Ginecologia i Medicina Preventiva i Salut Pública) ;
van Laarhoven, J. (Jeroen Bosch Ziekenhuis. Department of General Surgery) ;
Otero-Piñeiro, A. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Bravo, R. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Visser, T. (Gelderse Vallei Hospital. Department of Surgery) ;
van Poppel, R. (Gelderse Vallei Hospital. Department of Surgery) ;
Valverde, S. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Hompes, Roel (Cancer Center Amsterdam. Department of Surgery, Amsterdam University Medical Centers, University of Amsterdam) ;
Sietses, C. (Gelderse Vallei Hospital. Department of Surgery) ;
Castells, Antoni (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Bemelman, W. A. (Cancer Center Amsterdam. Department of Surgery, Amsterdam University Medical Centers, University of Amsterdam) ;
Tanis, P. J. (Cancer Center Amsterdam. Department of Surgery, Amsterdam University Medical Centers, University of Amsterdam) ;
Lacy Fortuny, Antonio Ma. de (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
For patients with mid and distal rectal cancer, robust evidence on long-term outcome and causal treatment effects of transanal total mesorectal excision (TaTME) is lacking. This multicentre retrospective cohort study aimed to assess whether TaTME reduces locoregional recurrence rate compared to laparoscopic total mesorectal excision (LapTME). [...]
2020 - 10.1186/s12885-020-07171-y
BMC Cancer, Vol. 20 (july 2020)
|
|
|
10.
|
|
7 p, 406.2 KB |
Genetic polymorphisms of FAS and EVER genes in a Greek population and their susceptibility to cervical cancer : a case control study
/
Pavlidou, Evangelia. (Geneva University Hospitals (Suïssa)) ;
Daponte, Alexandros (University of Thessaly. Department of Obstetrics and Gynaecology. Faculty of Medicine) ;
Egea, Raquel (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
Dardiotis, Efthimios (University of Thessaly. Department of Neurology) ;
Hadjigeorgiou, Georgios M. (University of Thessaly. Department of Neurology) ;
Barbadilla Prados, Antonio (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) ;
Agorastos, Theodoros (Hippokrateion General Hospital of Thessaloniki)
Background: the aim of the study was to evaluate the association of two SNPs of EVER1/2 genes' region (rs2290907, rs16970849) and the FAS-670 polymorphism with the susceptibility to precancerous lesions and cervical cancer in a Greek population. [...]
2016 - 10.1186/s12885-016-2960-3
BMC Cancer, Vol. 16 (2016) , art. 923
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
